May Nesfatin-1 is a New Marker of Inflammation in Varicose Veins?

Yıl 2025, Cilt: 20 Sayı: 1, 58 - 64

Mehmet Kirişci , Sezen Koçarslan

https://doi.org/10.17517/ksutfd.1525932

Öz

Objective: The expression of nesfatin-1, an anti-inflammatory peptide, in varicose saphenous veins, may indicate the inflammation process in these veins. For this purpose, we aimed to determine the presence nesfatin-1 in varicose veins.

Materials and methods: In this study, varicose vein samples have been taken from 50 patients with varicose veins. For the control group, vena saphena magna tissue samples taken out for coronary bypass were obtained from 50 patients. Immunohistochemical staining was performed by staining tissues with nesfatin-1 antibody and two groups were compared.

Results: In the immunostaining of nesfatin-1 on varicose vein samples, 38 (76%) patients were determined to be positive, and no staining was observed in 12 (24%) patients. In saphenous tissue samples taken from the control group, 10 samples (20%) were stained positive with nesfatin immunostaining, while 40 samples (80%) were not stained. Staining of varicose veins with nesfatin immunostaining showed a statistically significant difference compared to the staining of samples taken from the control group (p<0.0001).

Conclusion: When compared to healthy veins, it was demonstrated that the varicose
etiopathogenesis. It is concluded that the expression of nesfatin-1, which is an anti-inflammatory peptide, in varicose veins may be a response to the inflammatory process.

Anahtar Kelimeler

Nesfatin 1, Varicose vein, Inflammation, Coronary bypass

Nesfatin-1, Varisli Damarlarda İnflamasyonun Yeni Bir Belirteci Olabilir Mi?

Öz

Amaç: Varisli safen venlerinde bir anti-inflamatuar peptid olan nesfatin-1'in ekspresyonu, bu damarlarındaki inflamasyon sürecinin bir göstergesi olabilir. Bu amaçla, varisli venlerde nesfatin-1'in varlığını belirlemeyi hedefledik.
Gereç ve yöntemler: Bu çalışmada, varisli ven örnekleri 50 varis hastasından alındı. Kontrol grubu için, koroner bypass amacıyla alınan vena safena magna doku örnekleri 50 hastadan elde edildi. Nesfatin-1 antikoru ile immünohistokimyasal boyama yapıldı ve iki grup karşılaştırıldı.
Bulgular: Varisli ven örneklerinde nesfatin-1 immünohistokimyası yapıldığında, 38 (%76) hastada pozitif boyama saptandı, 12 (%24) hastada ise boyama gözlemlenmedi. Kontrol grubundan alınan safen ven dokusu örneklerinde ise 10 örnek (%20) nesfatin ile pozitif boyandı, 40 örnek (%80) ise boyanmadı. Varisli venlerde nesfatin immünohistokimyası ile yapılan boyama, kontrol grubundaki örneklerin boyama sonuçları ile istatistiksel olarak anlamlı bir fark gösterdi (p<0,0001).
Sonuç: Sağlıklı venlerle karşılaştırıldığında, varisli venlerin nesfatin-1 ile güçlü bir şekilde boyandığı gösterilmiştir. Nesfatin-1'in varisli venlerdeki ekspresyonu, inflamasyon sürecine bir yanıt olabilir ve varisli venlerin etiyopatogenezi açısından önemli bir rol oynayabilir. Nesfatin-1'in bir anti-inflamatuar peptid olarak varisli venlerdeki ifadesi, inflamasyon sürecine bir yanıt olabilir.

Anahtar Kelimeler

Nesfatin 1, Varisli ven, İnflamasyon, Koroner bypass

Kaynakça

• Evans CJ, Fowkes FG, Ruckley CV, Lee AJ. Prevalence of varicose veins and chronic venous insufficiency in men and women in the general population: Edinburgh Vein Study. J Epidemiol Comm Health. 1999;53:149-53.
• Chwała M, Szczeklik W, Szczeklik M, Aleksiejew-Kleszczynski T, Jagielska-Chwała M. Varicose veins of lower extremities, hemodynamics and treatment methods. Adv Clin Exp Med. 2015;24:5-14.
• Krysa J, Jones GT, van Rij AM. Evidence for a genetic role in varicose veins and chronic venous insufficiency. Phlebology. 2012;27:329-35.
• Scott TE, LaMorte WW, Gorin DR, Menzoian JO. Risk factors for chronic venous insufficiency: a dual case-control study. J Vasc Surg. 1995;22:622–8.
• Jawien A. The influence of environmental factors in chronic venous insufficiency. Angiology. 2003;54: 19–31.
• Myara I, Myara A, Mangeot M, Fabre M, Charpentier C, Lemonnier A. Plasma prolidase activity: a possible index of collagen catabolism in chronic liver disease. Clin Chem. 1984;30: 211-5.
• Rose SS, Ahmed A. Some thoughts on the aetiology of varicose veins. J Cardiovasc Surg. 1986;27(5):534-43.
• Birdina J, Pilmane M, Ligers A. The Morphofunctional Changes in the Wall of Varicose Veins. Ann Vasc Surg. 2017;42:274-84.
• Vural M, Toy H, Camuzcuoglu H, Aksoy N. Comparison of prolidase enzyme activities of maternal serum and placental tissue in patients with early pregnancy failure. Arch Gynecol Obstet. 2011;283:953-8.
• Oh-I S, Shimizu H, Satoh T, Okada S, Adachi S, Inoue K, et al. Identification of nesfatin-1 as a satiety molecule in the hypothalamus. Nature. 2006;443(7112):709-12.
• Yosten GL, Samson WK. Nesfatin-1 exerts cardiovascular actions in brain: possible interaction with the central melanocortin system. Am. J. Physiol. Regul. Interg. Comp. Physiol. 2009;297:330–6.
• C Ayada, U Toru, Y Korkut. Nesfatin-1 and its effects on different systems. Hippokratia. 2015;19:4–10.
• Ramanjaneya M, Chen J, Brown JE, Tripathi G, Hallschmid M, Patel S, et al. Identification of nesfatin-1 in human and murine adipose tissue: a novel depot-specific adipokine with increased levels in obesity. Endocrinology. 2010;151(7):3169-80.
• Foo KS, Brauner H, Ostenson CG, Broberger C. Nucleobindin-2/ nesfatin in the endocrine pancreas: distribution and relationship to glycaemic state. J Endocrinol. 2010;204:255–63.
• Osaki A, Shimizu H, Ishizuka N, Suzuki Y, Mori M, Inoue S. Enhanced expression of nesfatin/nucleobindin-2 in white adipose tissue of ventromedial hypothalamus-lesioned rats. Neurosci Lett. 2012;521:46–51.
• CH Tang, X-J Fu, X-L Xu, X-J Wei, H-S Pan. The anti-inflammatory and antiapoptotic effects of nesfatin-1 in the traumatic rat brain, Peptides. 2012;36:39–45.
• Low Wang CC, Hess CN, Hiatt WR, Goldfine AB. Clinical Update: Cardiovascular Disease in Diabetes Mellitus: Atherosclerotic Cardiovascular Disease and Heart Failure in Type 2 Diabetes Mellitus - Mechanisms, Management, and Clinical Considerations. Circulation. 2016;133:2459-502.
• Naoum JJ, Hunter GC, Woodside KJ, Chen C. Current advances in the pathogenesis of, varicose veins. J Surg Res. 2007;141:311–6.
• Michiels C, Bouaziz N, Remacle J. Role of the endothelium and blood stasis in the development of varicose veins. Int Angiol. 2002;21:18–25.
• Eberhardt RT, Raffetto JD. Chronic venous insufficiency. Circulation. 2014;130:333-346
• Raffetto JD, Khalil RA. Mechanisms of varicose vein formation: valve dysfunction and wall dilation. Phlebology. 2008;23:85-98.
• Raffetto JD, Mannello F. Pathophysiology of chronic venous disease. Int Angiol. 2014;33: 212-21.
• Ono T, Bergan JJ, Schmid-Schönbein GW, Takase S. Monocyte infiltration into venous valves. J Vasc Surg. 1998;27:158–66.
• Mannello F, Ligi D, Raffetto JD. Glycosaminoglycan sulodexide modulates inflammatory pathways in chronic venous disease. Int Angiol. 2014;33:236-42.
• Kocarslan A, Kocarslan S. What is the role of prolidase in pathogenesis of primary varicose veins? Turkish Journal of Thoracic And Cardiovascular Surgery. 2017;25(1):68-73.
• Akar I, Ince I, Aslan C, Benli I, Demir O, Altindeger N. et al. Oxidative stress and prolidase enzyme activity in the pathogenesis of primary varicose veins. Vascular. 2018;26(3):315-21.
• Horecka A, Biernacka J, Hordyjewska A, Dąbrowski W, Terlecki P, Zubilewicz T, et al. Antioxidative mechanism in the course of varicose veins. Phlebology. 2018;33(7):464-9.
• Zuo H, Shi Z, Yuan B, Dai Y, Wu G, Hussain A. Association between serum leptin concentrations and insulin resistance: a population-based study from China. PLoS ONE. 2013;8:e54615.
• Gunay H, Tutuncu R, Aydin S, Dag E, Abasli D. Decreased plasma nesfatin-1 levels in patients with generalized anxiety disorder. Psychoneuroendocrinology. 2012;37:1949–53.
• Aydin S, Dag E, Ozkan Y, Erman F, Dagli AF, et al. Nesfatin-1 and ghrelin levels in serum and saliva of epileptic patients: hormonal changes can have a major effect on seizure disorders. Mol Cell Biochem. 2009;328(1-2):49-56.
• Ding S, Qu W, Dang S, Xie X, Xu J, Wang Y, et al. Serum nesfatin-1 is reduced in type 2 diabetes mellitus patients with peripheral arterial disease. Med Sci Monit. 2015;21:987-91.
• Dai H, Li X, He T, Wang Y, Wang Z, Wang S, et al. Decreased plasma nesfatin-1 levels in patients with acute myocardial infarction. Peptides. 2013;46:167-71.
• Ozsavci D, Ersahin M, Sener A, Ozakpinar OB, Toklu HZ, Akakin D, et al. The novel function of nesfatin-1 as an anti-inflammatory and antiapoptotic peptide in subarachnoid hemorrhage-induced oxidative brain damage in rats. Neurosurgery. 2011;68(6):1699-708.
• Erfani S, Moghimi A, Aboutaleb N, Khaksari M. Protective effects of Nesfatin-1 peptide on cerebral ischemia reperfusion injury via inhibition of neuronal cell death and enhancement of antioxidant defenses. Metab Brain Dis. 2019;34(1):79-85.
• Scotece M, Conde J, Abella V, López V, Lago F, Pino J, et al. NUCB2/nesfatin-1: a new adipokine expressed in human and murine chondrocytes with pro-inflammatory properties, an in vitro study. J Orthop Res. 2014;32(5):653-60.
• Kuyumcu A. The relationship between nesfatin-1 and carotid artery stenosis. Scand Cardiovasc J. 2018;52(6):328-34.
• Zhang Z, Li L, Yang M, Liu H, Boden G, Yang G. Increased plasma levels of nesfatin-1 in patients with newly diagnosed type 2 diabetes mellitus. Exp Clin Endocrinol Diabetes. 2012;120(2):91-5.
• Li QC, Wang HY, Chen X, Guan HZ, Jiang ZY. Fasting plasma levels of nesfatin-1 in patients with type 1 and type 2 diabetes mellitus and the nutrient-related fluctuation of nesfatin-1 level in normal humans. Regul Pept. 2010;159(1-3):72-7.
• Gunes H, Alkan Baylan F, Gunes H, Temiz F. Can Nesfatin-1 Predict Hypertension in Obese Children. J Clin Res Pediatr Endocrinol. 2020;12(1):29-36.